Please select the eligibility criteria that correspond to the clinical trial below.
Title: Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
Brief Summary: Obese patients undergoing bariatric surgery warrant VTE prophylaxis because they are at high risk for developing a fatal pulmonary embolism or postthrombotic syndrome. However, a consensus does not exist on the most effective prophylactic approach.


Options:
A: Inclusion Criteria:

* BMI \>40 OR \>35 with comorbidities

Exclusion Criteria:

* No
B: Inclusion Criteria:

* Age \>18 years old
* COVID-19 positive on (RT-PCR) nasopharyngeal swab, or suspected COVID-19 infection with detectable SARS-CoV-2 IgG or IgM.
* Intensive care unit (ICU) patient or non-ICU patient on invasive mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or supplemental oxygen of at least 4 liters per minute nasal cannula.
* D dimer level greater than 700 ng/mL (3 times the upper limit of normal).

Exclusion Criteria:

* Objectively documented deep vein thrombosis or pulmonary embolism
* Patients in whom there is very high suspicion for pulmonary embolism and are on full-dose anticoagulation as per the treating physician
* Platelets \<30,000 not due to disseminated intravascular coagulation (DIC), based on the International Society of Thrombosis and Haemostasis (ISTH) criteria and American Society of Hematology (ASH) Frequently Asked Questions
* Active bleeding that poses a contraindication to therapeutic anticoagulation in the opinion of the investigator.
* History of bleeding diathesis (e.g., hemophilia, severe von Willebrand disease, severe thrombocytopathy)
* History of intracranial hemorrhage in the last 90 days
* History of ischemic stroke in the past 2 weeks
* Major neurosurgical procedure in the past 30 days
* Cardiothoracic surgery in the past 30 days
* Intra-abdominal surgery in the past 30 days
* Intracranial malignancy
* Patients who require therapeutic anticoagulation for other reasons like atrial fibrillation, deep venous thrombosis, pulmonary embolism, or antiphospholipid syndrome.
C: Inclusion Criteria:

1. Age ≥18 years (male or female)
2. Acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
3. Currently admitted to an intensive care unit (ICU)

Key Exclusion Criteria:

1. Ongoing (\>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication
2. Ongoing or planned treatment with dual antiplatelet therapy
3. Contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following:

   1. History of intracranial hemorrhage, known central nervous system (CNS) tumor or CNS vascular abnormality
   2. Active or recent major bleeding within the past 30 days with untreated source
   3. Platelet count \<70,000 or known functional platelet disorder
   4. Fibrinogen \<200 mg/dL
   5. International normalized ratio (INR) \>1.9
4. History of heparin-induced thrombocytopenia
5. Ischemic stroke within the past 2 weeks

Patients who meet the following criterion are excluded from the second randomization (antiplatelet therapy vs. no antiplatelet therapy):

1. Ongoing or planned antiplatelet therapy, including aspirin monotherapy
D: Inclusion Criteria:

* Confirmed diagnosis of COVID-19 by RT-PCR or serology with presence of IgM positive antibodies;
* Lung image (X-ray or chest CT) with involvement of at least 25% of the parenchyma;
* O2 saturation in ambient air less than or equal to 93%
* Alteration of inflammatory tests

  * D-Dimer above the reference value and
  * Elevation of C-reactive protein, ferritin or lactic dehydrogenase
* Sign the consent form.

Exclusion Criteria:

* QT interval prolongation
* Imminence of orotracheal intubation (intubation prediction in the first 4 hours after randomization)
* Women who are pregnant or breastfeeding
* Corticosteroid allergy or intolerance
* Chronic corticosteroid users (prednisone equivalent \> 10 mg daily)
* Patients diagnosed with cancer with increased bleeding potential
* Patients in hemodialysis
* History of peptic ulcer
* Herpes zoster infection
* History or active treatment of tuberculosis
* Systemic fungal infection
* Use of anticoagulation due to previous pathology
* Glaucoma
* Live virus vaccine up to 90 days before randomization
* Known coagulopathy or thrombocytopenia (\<40,000/mm3) or hypofibrinogenemia (\< 50 mg/dL)
* Recent bleeding
* Another limiting comorbidity for administering the therapies provided for in this protocol in in researcher's opinion

Answer: A